Golo Ahlenstiel

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7193597/golo-ahlenstiel-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101 4,671 27 67 g-index

141 5,320 5.7 5.26 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
101	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ Tcell responses <i>Cell Reports</i> , 2022 , 110345	10.6	3
100	HBV vaccination and HBV infection induces HBV-specific natural killer cell memory. <i>Gut</i> , 2021 , 70, 357-	369).2	14
99	Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study. <i>Nutrients</i> , 2021 , 13,	6.7	1
98	Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohnß Disease. <i>Inflammatory Bowel Diseases</i> , 2021 ,	4.5	3
97	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3288-e3295	11.6	4
96	Interferon-B Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis. <i>Journal of Inflammation Research</i> , 2021 , 14, 1257-1270	4.8	5
95	Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. <i>Oncologist</i> , 2021 , 26, e1216-e1225	5.7	7
94	A retrospective case-control cohort analysis of comorbidity and health expenditure in hospitalized adults diagnosed with obesity utilizing ICD-10 diagnostic coding. <i>Clinical Obesity</i> , 2021 , 11, e12469	3.6	
93	Examining the gut-liver axis in liver cancer using organoid models. <i>Cancer Letters</i> , 2021 , 510, 48-58	9.9	5
92	The prevalence of small-bowel polyps on video capsule endoscopy in patients with sporadic duodenal or ampullary adenomas. <i>Gastrointestinal Endoscopy</i> , 2021 , 93, 630-636	5.2	2
91	Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1183-1195	7	6
90	Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey. <i>BMJ Open Gastroenterology</i> , 2021 , 8,	3.9	13
89	Estimating the Economic Burden of Low Health Literacy in the Blacktown Community in Sydney, Australia: A Population-Based Study. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
88	Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study. <i>BMJ Open</i> , 2021 , 11, e042493	3	1
87	Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. <i>Cancers</i> , 2021 , 13,	6.6	4
86	Targeting Gutliver Axis for Treatment of Liver Fibrosis and Portal Hypertension. <i>Livers</i> , 2021 , 1, 147-17	79	O
85	Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue. <i>Frontiers in Immunology</i> , 2021 , 12, 727952	8.4	1

84	Expansion of dysfunctional CD56-CD16+ NK cells in chronic hepatitis B patients. <i>Liver International</i> , 2021 , 41, 969-981	7.9	4
83	Non-coding RNA and immune-checkpoint inhibitors: friends or foes?. <i>Immunotherapy</i> , 2020 , 12, 513-52	9 3.8	8
82	The Use of Two-Dimensional Shear Wave Elastography in People with Obesity for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2020 , 10,	5.1	5
81	Pre-treatment predictors of immune-mediated hepatitis in non-small cell lung cancer patients treated with immune-checkpoint inhibitors: A retrospective study <i>Journal of Clinical Oncology</i> , 2020 , 38, e15136-e15136	2.2	
80	Landscape of immune-checkpoint inhibitors in hepatocellular carcinoma: A systematic review with meta-analysis <i>Journal of Clinical Oncology</i> , 2020 , 38, e16632-e16632	2.2	
79	Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. <i>Clinical and Experimental Immunology</i> , 2020 , 202, 335-352	6.2	3
78	Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020 , 1873, 188350	11.2	9
77	Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
76	The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus. <i>Cells</i> , 2019 , 8,	7.9	23
75	Interferon Lambda and Liver Fibrosis. <i>Journal of Interferon and Cytokine Research</i> , 2019 , 39, 627-635	3.5	6
74	The Role of Zinc in Antiviral Immunity. Advances in Nutrition, 2019, 10, 696-710	10	292
73	KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. <i>Journal of Hepatology</i> , 2019 , 71, 252-264	13.4	22
72	Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis. <i>European Journal of Cancer</i> , 2019 , 110, S21-S22	7.5	
71	CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury. <i>PLoS ONE</i> , 2019 , 14, e0215557	3.7	4
70	Pharmacogenetics of anticancer monoclonal antibodies. 2019 , 2, 69-81		1
69	The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. <i>Cells</i> , 2019 , 8,	7.9	19
68			
00	Macrophage Coordination of the Interferon Lambda Immune Response. <i>Frontiers in Immunology</i> , 2019 , 10, 2674	8.4	26

66	The antiviral role of zinc and metallothioneins in hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 491-501	3.4	24
65	Gastric Cancer Screening in Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2018 , 38, 768-777	5.7	13
64	Adiponectin confers protection from acute colitis and restricts a B cell immune response. <i>Journal of Biological Chemistry</i> , 2017 , 292, 6569-6582	5.4	20
63	Zinc is a potent and specific inhibitor of IFN-B signalling. <i>Nature Communications</i> , 2017 , 8, 15245	17.4	38
62	Endoscopic resection of large duodenal and papillary lateral spreading lesions is clinically and economically advantageous compared with surgery. <i>Endoscopy</i> , 2017 , 49, 659-667	3.4	17
61	Compounded Levofloxacin Triple Therapy is Safe and Effective for Refractory Helicobacter pylori. <i>International Journal of Pharmaceutical Compounding</i> , 2017 , 21, 330-333	0.2	1
60	Validated computed cleansing score for video capsule endoscopy. <i>Digestive Endoscopy</i> , 2016 , 28, 564-9	3.7	12
59	IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. <i>Genes and Immunity</i> , 2016 , 17, 328-34	4.4	8
58	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016 , 64, 390-398	13.4	55
57	Interferon-Irs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422	17.4	127
57 56		17.4	127
	Nature Communications, 2015, 6, 6422 Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with	, ,	
56	Nature Communications, 2015, 6, 6422 Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. Journal of Medical Case Reports, 2015, 9, 210 Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck	1.2	4
56 55	Nature Communications, 2015, 6, 6422 Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. Journal of Medical Case Reports, 2015, 9, 210 Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. Gastroenterology Research and Practice, 2015, 2015, 612610 Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy	1.2	4 5
565554	Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. <i>Journal of Medical Case Reports</i> , 2015 , 9, 210 Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 612610 Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). <i>PLoS ONE</i> , 2015 , 10, e0134158 IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.	1.2 2 3.7	456
56555453	Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. <i>Journal of Medical Case Reports</i> , 2015 , 9, 210 Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 612610 Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). <i>PLoS ONE</i> , 2015 , 10, e0134158 IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014 , 61, 235-41 Ribavirin improves the IFN-Tresponse of natural killer cells to IFN-based therapy of hepatitis C virus	1.2 2 3.7 13.4	45633
5655545352	Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report. <i>Journal of Medical Case Reports</i> , 2015 , 9, 210 Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer. <i>Gastroenterology Research and Practice</i> , 2015 , 2015, 612610 Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART). <i>PLoS ONE</i> , 2015 , 10, e0134158 IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. <i>Journal of Hepatology</i> , 2014 , 61, 235-41 Ribavirin improves the IFN-Iresponse of natural killer cells to IFN-based therapy of hepatitis C virus infection. <i>Hepatology</i> , 2014 , 60, 1160-9 IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus	1.2 2 3.7 13.4 11.2	4 5 6 33 23

(2010-2014)

48	Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent. <i>Genes and Immunity</i> , 2014 , 15, 88-94	4.4	18
47	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014 , 63, 161-9	19.2	48
46	Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17830-8	5.6	8
45	Diagnosis and Treatment of Radiation Proctitis. <i>Video Journal and Encyclopedia of GI Endoscopy</i> , 2013 , 1, 316-317		
44	CCR5-B2 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. <i>Genes and Immunity</i> , 2013 , 14, 286-90	4.4	5
43	Ophthalmologic complications of antiviral therapy in hepatitis C treatment. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8227-37	5.6	7
42	The natural killer cell response to HCV infection. <i>Immune Network</i> , 2013 , 13, 168-76	6.1	17
41	Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7055-61	5.6	6
40	Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. <i>Hepatology</i> , 2012 , 55, 39-48	11.2	88
39	Pharmacogenomics of hepatitis C infections: personalizing therapy. <i>Genome Medicine</i> , 2012 , 4, 99	14.4	7
38	Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?. <i>Antiviral Therapy</i> , 2012 , 17, 1163-70	1.6	7
37	Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. <i>Gastroenterology</i> , 2011 , 141, 1231-9, 1239.e1-2	13.3	129
36	S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. <i>Gastroenterology</i> , 2011 , 140, 830-9	13.3	40
35	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. <i>Genome Medicine</i> , 2011 , 3, 57	14.4	57
34	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. <i>PLoS Medicine</i> , 2011 , 8, e1001092	11.6	93
33	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. <i>Gastroenterology</i> , 2010 , 138, 325-35.e1-2	13.3	211
32	The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. <i>European Journal of Medical Research</i> , 2010 , 15, 102-11	4.8	9
31	IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. <i>Journal of Gastroenterology</i> , 2010 , 45, 903-10	6.9	41

30	Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology, 2009 , 49, 12-21	11.2	87
29	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics, 2009, 41, 1100-4	36.3	1636
28	Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2009 , 9, 847-52	4.5	9
27	Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia. <i>Immunological Investigations</i> , 2009 , 38, 284-96	2.9	7
26	Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia. <i>Immunological Investigations</i> , 2009 , 38, 1-13	2.9	4
25	State-of-the-Art Lecture: The liver as an immune organ 2009 , 77-86		
24	Description of two new major histocompatibility complex (MHC) class II DRB1 [Pan troglodytes (Patr)-DRB1] alleles. <i>Tissue Antigens</i> , 2008 , 71, 490-2		1
23	Identification of new major histocompatibility complex-A, -B, -C alleles in chimpanzees (Pan troglodytes). <i>Tissue Antigens</i> , 2008 , 72, 79-83		
22	Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. <i>Gastroenterology</i> , 2008 , 135, 2107-18	13.3	31
21	The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. <i>Aids</i> , 2008 , 22, 1287-92	3.5	13
20	Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. <i>Journal of Clinical Investigation</i> , 2008 , 118, 1017-26	15.9	124
19	Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. <i>Vaccine Journal</i> , 2007 , 14, 1266-73		13
18	The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. <i>Journal of Hepatology</i> , 2007 , 47, 348-55	13.4	9
17	Hepatic NK, NKT, and T Cells 2007 , 71-82		2
16	Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. <i>Endoscopy</i> , 2006 , 38, 604-9	3.4	18
15	Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. <i>Gut</i> , 2006 , 55, 869-77	19.2	185
14	The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 42-6	3.4	19
13	Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. <i>European Journal of Medical Research</i> , 2006 , 11, 273-8	4.8	2

LIST OF PUBLICATIONS

12	The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. <i>American Journal of Pathology</i> , 2005 , 166, 443-53	5.8	135
11	Hepatitis C virus and the threshold of natural killer cell inhibition. <i>Hepatology</i> , 2005 , 41, 675-7	11.2	4
10	Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection a prospective cross-sectional study. <i>World Journal of Gastroenterology</i> , 2005 , 11, 7631-8	5.6	12
9	HIV-1 Infection Leads to Increased HLA-E Expression Resulting in Impaired Function of Natural Killer Cells. <i>Antiviral Therapy</i> , 2005 , 10, 95-107	1.6	102
8	CC-chemokine receptor 5 (CCR5) in hepatitis Cat the crossroads of the antiviral immune response?. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 895-8	5.1	27
7	Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 519-26	3.4	30
6	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004 , 41, 652-8	13.4	50
5	420 Reduced intrahepatic expression of DC-SignR in. <i>Journal of Hepatology</i> , 2004 , 40, 124	13.4	128
4	HCV chronic infection and CCR5-delta32/delta32. <i>Gastroenterology</i> , 2003 , 124, 868-9; author reply 869-	70 3.3	25
3	Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 2003 , 39, 245-52	13.4	35
2	Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. <i>Gastroenterology</i> , 2002 , 122, 1721-8	13.3	104
1	Increased frequency of the CC-chemokine receptor 5-D32/D32 genotype in hepatitis C. <i>Journal of Hepatology</i> , 2001 , 34, 164	13.4	2